We have written extensively about health system regulation in this blog, with a keen interest in how LDT regulation will shake out. In our other blog we’ve even argued strongly for caution in LDT regulation, primarily to avoid stifling innovation. However, our...
At Amplion we have a commercial interest in access to high quality clinical information that can inform and contribute to our flagship product, BiomarkerBase. However, we are truly passionate about contributing to higher quality, more personalized, medical...
In our Chart of the Week post from last week we presented an analysis of the number of unique biomarkers being used by leading drug developers in their clinical trials (unique biomarkers being defined as those that aren’t being used by any other companies). This...
Diagnostic tests with algorithms seem to slow review periods on average. Share this Image On Your Site <p><strong>Please include attribution to https://amplion.wpengine.com/biomarker-trends with this graphic.</strong><br /><br /><a...
We’ve covered the LDT regulation evolution for some time now. To give some perspective we’ve created the following infographic showing the history of LDT regulation. To use it in your own content check out the code snippet below the infographic. We only...